Buprenorphine Market Analysis

Report ID: 3193
Published Date: Dec 26, 2024
Report Format: PDF, PPT

Buy Now

Buprenorphine Segmentation

The market is segmented by route of administration into sublingual, transdermal, and buccal, out of which, the sublingual segment is anticipated to hold the largest share in the buprenorphine market on account of the increasing availability of buprenorphine drugs in several dosages in the sublingual form. Along with this, rapid drug absorption, first-pass metabolism and quick onset of action of sublingual route of administration are also predicted to boost the growth of the market segment in the forecast period. Additionally, the segment for buccal dosage is expected to witness notable growth in the future, which can be credited to the increasing number of people opting for oral drugs as compared to injection-based drugs.

Our in-depth analysis of the global market includes the following segments

By Route Of Administration

Sublingual
Transdermal
Buccal

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Browse key industry insights with market data tables & charts from the report:

Buprenorphine Market Size & Share, Growth Trends 2037

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of buprenorphine is assessed at USD 6.98 billion.

Buprenorphine Market size was valued at USD 6.22 billion in 2024 and is expected to reach USD 35.75 billion by 2037, expanding at around 14.4% CAGR during the forecast period i.e., between 2025-2037.

North America industry is set to account for largest revenue share by 2037, on the back of strong presence of market players and growing percentage of the population suffering from opioid dependency in the region.

The major players in the market are The Siegfried Group, LLP, Johnson Matthey Group, Purdue Pharma LP, Pharmaforce Inc., Hikma Pharmaceuticals PLC, and others.